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Coronavirus Disease-2019 in Heart Transplant Recipients in
Southeastern Michigan: A Case Series
SCOTT W. KETCHAM, MD,1 SARAH K. ADIE, PHARMD,2 ASHLEY MALLIETT, MS,3 AHMAD A. ABDUL-AZIZ, MD,4
ABBAS BITAR, MD,4 GILLIAN GRAFTON, DO,3 AND MATTHEW C. KONERMAN, MD4
Ann Arbor, and Detroit, Michigan
ABSTRACT
Background: Since coronavirus disease 2019 (COVID-19) was first identified in Wuhan, China, in
December 2019, the number of cases has risen exponentially. Clinical characteristics and outcomes among
patients with orthotopic heart transplant (OHT) with COVID-19 remain poorly described.
Methods: We performed a retrospective case series of patients with OHT with COVID-19 admitted to 1 of
2 hospitals in Southeastern Michigan between March 21 and April 22, 2020. Clinical data were obtained
through review of the electronic medical record. Final date of follow-up was May 7, 2020. Demographic,
clinical, laboratory, radiologic, treatment, and mortality data were collected and analyzed.
Results: We identified 13 patients with OHT admitted with COVID-19. The mean age of patients was 61
§ 12 years, 100% were black males, and symptoms began 6 § 4 days before admission. The most common
symptoms included subjective fever (92%), shortness of breath (85%), and cough (77%). Six patients
(46%) required admission to the intensive care unit. Two patients (15%) died during hospitalization.
Conclusions: Black men may be at increased risk for COVID-19 among patients with OHT. Presenting
signs and symptoms in this cohort are similar to those in the general population. Elevated inflammatory
markers on presentation appear to be associated with more severe illness. (J Cardiac Fail
2020;26:457461)
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Coronavirus disease 2019 (COVID-19) is the illness
caused by severe acute respiratory syndrome coronavirus-2,
first detected in Wuhan, China. Although COVID-19 most
commonly causes a mild respiratory illness, there are wide
ranges of presenting symptoms and disease severity. Owing
to the immunosuppression required to prevent allograft
rejection, patients with orthotopic heart transplantation
(OHT) represent a population who may have an atypical
presentation or be at higher risk for adverse outcomes from
COVID-19. Currently, COVID-19 in patients with OHT
remains poorly characterized.1 We describe the presenta-
tion, course, and outcomes of patients with OHT hospital-
ized for COVID-19.
Material and Methods
Study Population and Setting
We included adult patients (18 years) with OHT with lab-
oratory-confirmed COVID-19 admitted to 1 of 2 hospitals in
Southeastern Michigan from March 21 to April 22, 2020. The
final date of follow-up was May 7, 2020. A confirmed case of
COVID-19 was defined as a positive result on a reverse-tran-
scriptase polymerase chain reaction assay of a nasopharyngeal
swab specimen. The institutional review boards at Michigan
Medicine and Henry Ford Health System approved this study.
Data Collection
Data were collected through review of OHT databases
and electronic medical records. Data included demo-
graphics, clinical history, laboratory and radiologic results,
and therapies administered.
Statistical Methods
Descriptive statistics were used to summarize the data.
Results are reported as medians and interquartile ranges or
means and standard deviations as appropriate. Categorical
variables were summarized as counts and percentages.
Analysis was performed with Microsoft Excel (Microsoft,
Redmond, WA).
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Results
Demographics and Medical History
More than 375 heart transplantations have been performed at
Michigan Medicine since 2006. Recipients from 2006 to 2018
had a median age of 55 years at time of transplantation. The
majority were male (78%) and white (81%), with 16% black.
At Henry Ford, more than 200 heart transplants have been per-
formed since 2006. Recipients from 2006 to 2019 had a median
age of 54 years at time of transplantation. The majority were
male (79%) and white (56%), with 39% black.
From March 21 to April 22, 2020, 13 adult patients with
OHT were hospitalized for COVID-19, 8 admitted to Michigan
Medicine and 5 to Henry Ford Hospital. No patients were diag-
nosed via asymptomatic screening. The mean age was 61 §
12 years (range, 3477 years). All were black males. Comorbid
conditions were common, including hypertension (85%),
chronic kidney disease (85%), and diabetes mellitus (69%;
Table 1). Two patients were heart-kidney transplant recipients
and one was a heartlung transplant recipient.
The average time from OHT to presentation was 9.6 §
6.3 years (range, 1.522.7). Heart failure or left ventricular





(N = 7/13 [54%])
Intensive Care
(N = 6/13 [46%])
Enrollment site  no. (%)
Michigan Medicine, Ann Arbor, MI 8/13 (62) 2/7 (29) 6/6 (100)
Henry Ford Hospital, Detroit, MI 5/13 (38) 5/7 (71) 0/6 (0)
Demographics
Mean age (range), years 61 (3477) 65 (5277) 57 (3473)
Male sex, no./total no. (%) 13/13 (100) 7/7 (100) 6/6 (100)
Body-mass index,* mean § SD 29 § 8 27 § 5 32 § 9
Black race, no./total no. (%) 13/13 (100) 7/7 (100) 6/6 (100)
Baseline transplant and immunosuppression information
Time since heart transplant, years, median (IQR) 8 (514) 8 (613) 9 (414)
Use of calcineurin inhibitor before diagnosis,
no./total no. (%)
12/13 (92) 7/7 (100) 5/6 (83)
Use of prednisone before admission, no./total
no. (%)
7/13 (54) 3/7 (43) 4/6 (67)
Use of mycophenolate mofetil before admission,
no./total no. (%)
7/13 (54) 5/7 (71) 2/6 (33)
Coexisting disorder, no./total no. (%)
Chronic anemia 8/13 (62) 5/7 (71) 3/6 (50)
Chronic heart failurey 5/13 (38) 1/7 (14) 4/6 (67)
Chronic kidney diseasez 11/13 (85) 7/7 (100) 4/6 (67)
Coronary artery diseasex 6/13 (46) 2/7 (29) 4/6 (67)
Former tobacco smoker 7/13 (54) 6/7 (86) 1/6 (17)
Diabetes mellitus 9/13 (69) 5/7 (71) 4/6 (67)
Hypertension 11/13 (85) 5/7 (71) 6/6 (100)
Obesity 5/13 (38) 2/7 (29) 3/6 (50)
Obstructive sleep apnea 6/13 (46) 3/7 (43) 3/6 (50)
Baseline laboratory values
Mean tacrolimus trough over prior 3 months
(ng/mL), median (IQR)
5.4 (4.86.0) 5.2 (4.85.9) 5.5 (5.26.5)
Most recent lymphocyte count (per mm3),
median (IQR)
1,600 (1,1002,300) 1,100 (1,0001,950) 1,885 (1,4062,443)
Most recent platelet count (per mm3), median
(IQR)
202,000 (159,000224,000) 203,000 (141,500219,000) 194,500 (166,000236,500)
Most recent high-sensitivity troponin 19 pg/mL,
no./total no. (%)
6/10 (60) 2/4 (50) 4/6 (66)
History
Duration of symptoms before diagnosis (days),
mean § SD
6 § 4 6 § 5 6 § 2
Symptom, no./total no. (%)
Fever 12/13 (92) 7/7 (100) 5/6 (83)
Cough 10/13 (77) 6/7 (86) 4/6 (67)
Shortness of breath 11/13 (85) 5/7 (71) 6/6 (100)
Diarrhea 6/13 (46) 4/7 (57) 2/6 (33)
Contact with health care system within 14 days
before admissionk
4/13 (31) 1/7 (14) 3/6 (50)
Reported sick contact without confirmed
COVID-19 diagnosis
7/13 (54) 5/7 (71) 2/6 (33)
*Body mass index measured as body weight in kilograms divided by body surface area in meters squared.
yDefined as requiring hospitalization for heart failure after heart transplant (or) history of heart failure requiring loop diuretic therapy before admission.
zDefined as an estimated glomerular filtration rate of <60 mL/min.
xDefined as cardiac allograft vasculopathy on intravascular ultrasound (or) any nonobstructive or obstructive disease on coronary angiogram (or) perfusion
defect or wall motion abnormality on stress imaging after heart transplantation.
kDefined as presentation to a health care facility, such as a hospital, clinic, or dialysis center for phlebotomy, hemodialysis, infusion, procedure, surgery,
outpatient visit, or emergency department presentation.
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systolic dysfunction was present in 5 patients (38%) and
cardiac allograft vasculopathy in 6 (46%). Before COVID-
19, a calcineurin inhibitor was prescribed in 12 patients
(83% tacrolimus), prednisone in 7 (54%), and mycopheno-
late in 7 (54%). The median of the 3-month individual aver-
age tacrolimus trough among patients prescribed tacrolimus
was 5.4 ng/mL (range, 4.86.0 ng/mL; Table 1).
Clinical Presentation
The mean duration of symptoms before admission was 6
§ 4 days (range, 114 days). The most common symptoms
included subjective fever (92%), shortness of breath (85%),
and cough (85%). Diarrhea occurred in 6 patients (46%;
Table 1). No patients were hospitalized within 30 days
before admission, had traveled outside the United States in
the 90 days before admission, or had known contact with an
individual who tested positive for COVID-19.
Objective Findings
Documented fever was present in 10 patients (77%) on
admission. Lymphopenia occurred in all patients and thrombo-
cytopenia in 8 (62%). Acute kidney injury occurred in the
majority (85%). High-sensitivity troponin was elevated in 7
patients (54%) and lactate was elevated in 5 patients (38%).
Elevated laboratory markers of inflammation were common,
with higher median values observed in patients requiring inten-
sive care. No patients had laboratory-confirmed coinfection on
presentation. The median tacrolimus trough on admission was
5.1 ng/mL (range, 2.86.0 ng/mL). Chest radiographs were
obtained in all patients and almost all (92%) showed bilateral
pulmonary infiltrates (Table 2).





(N = 7/13 [54%])
Intensive Care
(N = 6/13 [46%])
Vital signs*
Temperature >100.4˚F or 38˚C 10/13 (77) 4/7 (57) 6/6 (100)
Temperature <96.8˚F or 36˚C 1/13 (8) 0/7 (0) 1/6 (17)
Heart rate >100 beats per minute 9/13 (69) 5/7 (71) 4/6 (67)
Respiratory rate 20 breaths per minute 11/13 (85) 5/7 (71) 6/6 (100)
Cell countsy
White cell count/mm3 4800 (36006600) 3600 (30004800) 6550 (500011,550)
Lowest lymphocyte count
Per mm3 700 (400900) 700 (450850) 600 (425850)
<1500/mm3 13/13 (100) 7/7 (100) 6/6 (100)
Lowest platelet count
Per mm3 134,000 (120,000156,000) 133,000 (115166,000) 138,500 (123,500150,500)
<150,000/mm3 8/13 (62) 4/7 (57) 4/6 (67)
Chemistriesy
Acute kidney injuryz 11/13 (85) 6/7 (86) 5/6 (83)
High-sensitivity troponin 19 pg/mL 7/13 (54) 3/7 (43) 4/6 (67)
Lactate 2.0 mmol/L 5/13 (38) 1/7 (14) 4/6 (67)
Tacrolimus trough (ng/mL) 5.1 (2.86.0) 5.75 (4.76.5) 3.5 (1.75.0)
Inflammatory markersy
Highest D-dimer (mg/mL) 0.9 (0.51.8) 0.4 (0.30.7) 1.9 (1.26.0)
Highest ferritin (ng/mL) 1163 (5401828) 540 (3811030) 1502 (11662258)
Highest lactate dehydrogenase (U/L) 315 (215627) 215 (186285) 644 (626729)
Highest procalcitonin (ng/mL) 1.2 (0.47.5) 0.4 (0.310.2) 3.0 (0.66.8)
Chest radiograph with bilateral infiltrates,
no./total no. (%)
12/13 (92) 6/7 (86) 6/6 (100)
Medical therapies
Tocilizumab 3/13 (23) 0/7 (0) 3/6 (50)
Hydroxychloroquine 8/13 (62) 6/7 (86) 2/6 (33)
High-dose corticosteroidsx 8/13 (62) 3/7 (43) 5/6 (83)
Intensive care therapies, no/total no. (%)
Vasopressor use 5/13 (38)  5/6 (83)
Mechanical ventilation 5/13 (38)  5/6 (83)
Continuous renal replacement therapy 5/13 (38)  5/6 (83)
Neuromuscular blockade 5/13 (38)  5/6 (83)
Outcomes
Died in hospital 2/13 (15) 0/7 (0) 2/6 (33)
Discharged from hospital 9/13 (69) 7/7 (100) 2/6 (33)
Remain hospitalized 2/13 (15) 0/7 (0) 2/6 (33)
Length of hospital stay among those discharged
(days)
6 (311) 5 (39) 19 (829)
Values are median (interquartile range) or number/total number (%).
*Represents vital signs recorded within the first 24 hours of admission
yRepresents data resulted within the first 72 hours of admission unless noted otherwise.
zAcute kidney injury defined as rise in serum creatinine >0.3 within 48 hours (or) an increase in serum creatinine of >1.5 times baseline within 7 days.
xDefined as a prednisone-equivalent corticosteroid dose 2 times greater than outpatient dose.
Coronavirus Disease-2019 in Heart Transplant Recipients in Southeastern  Ketcham et al 459
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on August 12, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
Interventions
Among COVID-19specific experimental/empiric
therapies delivered, 3 patients (23%) received tocilizu-
mab, 8 (62%) received hydroxychloroquine, and 8
(62%) received high-dose corticosteroids. Vasopressors,
mechanical ventilation, neuromuscular blockade, and
continuous renal replacement therapy were required in 5
of the 6 patients (83%) requiring intensive care
(Table 2). Only 1 patient (8%) received inhaled pulmo-
nary vasodilators and prone positioning. No patients
received extracorporeal membrane oxygenation.
Among the 7 patients prescribed mycophenolate before
presentation, it was discontinued in 6 on presentation.
Although tacrolimus trough goals remained unchanged,
dose reduction was required in 6 patients (60% of all
patients on tacrolimus) to achieve the target range.
Outcomes
All patients had at least 15 days of follow-up. As of May
7, 2020, of the 13 admitted patients, 2 (15%) had died, 2
(15%) remain hospitalized in acute care, and 9 (69%) had
been discharged from the hospital (Fig. 1). The median
length of hospital stay among those discharged was 6 days
(range, 311 days; Table 2).
Discussion
To our knowledge, this is the first case series of a cohort
of patients with OHT hospitalized with COVID-19. There
are several notable observations.
All patients in this cohort were black males. Racial dispar-
ities in COVID-19 outcomes have been observed in several
states.2 In Michigan, 14% of the population is black, and 33%
of COVID-19 cases and 41% of deaths occurred in the black
community.3 Although this imbalance is potentially due to the
prevalence of comorbid conditions or health care disparities,
genetic polymorphisms in the renin-angiotensin system may
also contribute to this risk. Previous reports have identified
alterations in the renin-angiotensin system activity profile of
blacks.4 Severe acute respiratory syndrome coronavirus-2
enters human cells through angiotensin-converting enzyme 2
receptors and angiotensin II activity potentially contributes to
disease severity and organ damage.5 Owing to the small sam-
ple size of this case series, no definitive conclusions can be
drawn regarding COVID-19 susceptibility in black males with
OHT. As such, further research is needed to determine if dis-
ease severity and COVID-19 risk is greater in black males
with OHT and whether patient characteristics or treatments
specific to OHT can be modified to decrease this risk.
Patients with OHT seem to present with COVID-19 simi-
larly to patients without OHT, exhibiting a wide range of
Fig. 1. Outcomes of individual patients. The current condition of patients with orthotopic heart transplantation with coronavirus disease-2019.
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symptoms, but sharing the most common symptoms of
fever, cough, and shortness of breath. However, diarrhea
occurred more commonly than previously observed.6,7 In
addition, particularly among patients requiring intensive
care, comorbid conditions such as hypertension, diabetes
mellitus, heart failure, and chronic kidney disease were
common, as was cardiac allograft vasculopathy, a condition
unique to patients with OHT.
Patients with OHT requiring intensive care in this series
had significant elevations in markers of inflammation. This
occurred despite these patients requiring immunosuppression
to preserve allograft function. It seems that, similar to the
general population,8 these laboratory findings denote a
greater illness severity in patients with OHT with COVID-19
and may be used to risk stratify patients. Of note, although
elevated high-sensitivity troponin levels are seen in approxi-
mately 20% of COVID-19 cases,9 levels were elevated in
more than one-half of our cohort, although these levels were
also elevated before admission among the 10 patients for
whom these data were available. Lymphopenia and thrombo-
cytopenia rates were higher in this study compared with pre-
vious reports in the nontransplanted and kidney transplant
populations.7,10 This finding may be explained by a lower
baseline lymphocyte and thrombocyte count, yet median val-
ues of these cell counts were lower on admission. Although
myocardial injury has been associated with worse out-
comes,11 no signal of an association was evident in this small
series and no patients experienced cardiac complications.
Our study has several limitations. First, our sample size is
small and it may lack generalizability. Owing to sample
size, we were unable to detect significant differences
between critically ill patients and those not requiring inten-
sive care. We also cannot make any conclusions regarding
COVID-19specific treatments or the management of
immunosuppression in this setting, although it should be
noted that one-half of our cohort required dose reductions
of tacrolimus despite similar tacrolimus levels before and
on admission. Second, 2 patients (15%) remained hospital-
ized at the conclusion of data collection on May 7, 2020.
Outcomes for these patients are unknown. Last, this study
did not capture outcomes for patients treated in the outpa-
tient setting. This factor limits our understanding of the
spectrum of symptoms and disease severity among patients
with OHT with COVID-19.
Conclusions
In this case series of patients with OHT hospitalized at 2
centers in Southeastern Michigan, all patients were black
males, most of whom had comorbid conditions. Despite
immunosuppression, the clinical presentation and labora-
tory markers of disease severity showed similarities to what
has been observed in the general population. Further
research should focus on racial and gender disparities in
COVID-19 and on the identification of prognostic markers,
treatments, and appropriate immunosuppression modifica-
tions for patients with OHT with COVID-19.
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